



Artisan Global Opportunities Fund

MONTHLY
Commentary

Investor Class: ARTRX | Advisor Class: APDRX

As of 31 January 2017

Commentary

Following a turbulent Q4, global markets were quieter in January, with most closing in positive territory as investors seemingly await signs of greater clarity from the newly inaugurated US administration. Emerging markets effectively recovered Q4 losses, leading major global indices, and foreign stocks outperformed US. In a reversal from much of 2016, growth stocks outperformed value. At the sector level, technology stocks led and health care rebounded from Q4, while energy gave back some of its recent gains.

Our portfolio outperformed the MSCI AC World Index in January as share prices for a number of our larger holdings materially recovered after Q4's challenging environment. Among our top contributors were IHS Markit, Genmab and Boston Scientific. We believe IHS Markit is making progress consolidating its business following its 2016 merger. Shares were pressured in Q4—unfairly, in our view—as investors shifted their preference from secular-oriented stocks to more credit-sensitive, cyclical names. In our view, IHS Markit's fundamentals remain sound and the profit cycle potential compelling.

Genmab and Boston Scientific were similarly caught up in Q4's sentiment shift but have since fully retraced those losses. Genmab's drug Darzalex™ is producing positive clinical outcomes—increasing the likelihood it becomes the standard of care in multiple myeloma treatment. Meanwhile, Boston Scientific has resolved technical issues that slowed its Lotus™ heart valve launch, which is now set for later in 2017. We believe the company is well positioned to capitalize on its deep pipeline, penetrating a large market with its innovative, blockbuster-potential products. We are further attracted to Boston Scientific's capacity for margin expansion.

Among our few negative contributors in January were Regeneron and Nintendo, both of which were down only modestly. Shares of Regeneron have been pressured following a set-back in the company's patent case. There is now a not-insignificant possibility the court will remove its cholesterol-lowering drug, Praluent®, from US markets. We believe this risk is well understood by the market, and even without Praluent®, we expect Regeneron to continue growing based on its best-in-class R&D organization.

Nintendo has struggled with its recent mobile game releases, which have generally disappointed compared to the hugely successful Pokémon Go release in the summer of 2016. While some potential catalysts are ahead, including the launch of its latest hardware platform, Nintendo Switch, we are watching for signs the thesis is playing out as we anticipated.

Our process is focused on identifying franchises exposed to accelerating profit cycles with reasonable valuations. It is our belief that owning companies with these characteristics should lead to outperformance over full market cycles. We will continue to be disciplined and methodical in our approach.

Portfolio Details

	ARTRX	APDRX
Net Asset Value (NAV)	\$21.71	\$21.74
Inception	22 Sep 2008	1 Apr 2015
Expense Ratios		
Annual Report 30 Sep 2016	1.17%	1.08%
Prospectus 30 Sep 2016 ¹	1.18%	1.09%

¹See prospectus for more information.

Top 10 Holdings (% of total portfolio)

IHS Markit Ltd (United States)	9.0
Alphabet Inc (United States)	6.3
Visa Inc (United States)	5.0
Boston Scientific Corp (United States)	3.7
Genmab A/S (Denmark)	3.4
Facebook Inc (United States)	3.4
S&P Global Inc (United States)	3.1
LKQ Corp (United States)	2.8
Regeneron Pharmaceuticals Inc (United States)	2.7
Treasury Wine Estates Ltd (Australia)	2.4
TOTAL	41.9%

Source: Artisan Partners/FactSet (MSCI).

Sector Diversification (% of total portfolio equities)

	Fund	ACWI ¹
Consumer Discretionary	10.6	12.2
Consumer Staples	9.9	9.4
Energy	5.2	7.0
Financials	9.8	18.6
Health Care	16.1	11.0
Industrials	13.0	10.6
Information Technology	31.0	15.9
Materials	4.4	5.5
Real Estate	0.0	3.1
Telecommunication Services	0.0	3.6
Utilities	0.0	3.1
TOTAL	100.0%	100.0%

Source: Artisan Partners/FactSet (GICS)/MSCI. Cash represented 4.4% of the total portfolio. ¹MSCI All Country World Index.

Investment Results (%)

As of 31 January 2017	Average Annual Total Returns							
	MTD ¹	QTD ¹	YTD ¹	1 Yr	3 Yr	5 Yr	10 Yr	Inception
Investor Class: ARTRX	6.27	6.27	6.27	19.55	8.14	12.46	—	10.44
Advisor Class: APDRX	6.26	6.26	6.26	19.65	8.22	12.51	—	10.47
MSCI All Country World Index	2.73	2.73	2.73	17.93	5.49	8.72	—	6.08
As of 31 December 2016								
Investor Class: ARTRX	-1.78	-5.87	4.73	4.73	4.92	13.25	—	9.75
Advisor Class: APDRX	-1.78	-5.82	4.88	4.88	5.00	13.31	—	9.78
MSCI All Country World Index	2.16	1.19	7.86	7.86	3.13	9.36	—	5.80

Source: Artisan Partners/MSCI. ¹Returns for periods less than one year are not annualized. Advisor Class performance is that of the Investor Class from 22 September 2008 through the inception of the Advisor Class on 1 April 2015, and actual Advisor Class performance thereafter. Performance has not been adjusted to reflect the expenses of the Advisor Class for the period prior to the Class's inception, and Advisor Class performance results would differ if such expenses were reflected.

Past performance does not guarantee and is not a reliable indicator of future results. Investment returns and principal values will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than that shown. Call 800.344.1770 for current to most recent month-end performance. Performance may reflect agreements to limit a Fund's expenses, which would reduce performance if not in effect.

Region/Country Allocation (% of total portfolio equities)

REGION	Fund	ACWI ¹
AMERICAS	60.5	56.7
United States	60.5	53.4
EUROPE	16.2	20.3
United Kingdom	6.3	5.9
Denmark	3.6	0.5
France	2.3	3.2
Germany	2.2	3.0
Netherlands	1.9	1.1
PACIFIC BASIN	15.8	11.9
Japan	8.5	7.9
Australia	4.8	2.4
Hong Kong	2.6	1.1
EMERGING MARKETS	7.5	10.8
China	2.4	2.9
Brazil	1.6	0.9
Korea	1.0	1.6
Mexico	0.9	0.4
India	0.8	0.9
South Africa	0.7	0.7
MIDDLE EAST	—	0.2
TOTAL	100.0%	100.0%

Source: Artisan Partners/FactSet (MSCI). ¹MSCI All Country World Index. Countries held in the index, but not held in the portfolio, are not listed.

Team Leadership (Pictured left to right)



Portfolio Managers

Years of Investment Experience

James D. Hamel, CFA (Lead)	20
Matthew H. Kamm, CFA	17
Craigh A. Cepukenas, CFA	28
Jason L. White, CFA	17

Carefully consider the Fund's investment objective, risks and charges and expenses. This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by calling 800.344.1770. Read carefully before investing.

International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period.

MSCI All Country World Index measures the performance of developed and emerging markets. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The discussion of portfolio holdings does not constitute a recommendation of any individual security. These holdings comprise the following percentages of the Fund's total net assets as of 31 Jan 2017: Nintendo Co Ltd 1.8%. Securities named in the Commentary, but not listed as a Top Ten Holding or not listed here are not held in the Fund as of the date of this report. The portfolio managers' views and portfolio holdings are subject to change and the Fund disclaims any obligation to advise investors of such changes.

All information in this report includes all classes of shares, except performance and expense ratio information and as otherwise indicated, and is as of the date shown in the upper right hand corner unless otherwise indicated. Totals may not sum due to rounding.

The Global Industry Classification Standard (GICS[®]) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

Country exposure percentages reflect country designations as classified by MSCI as of the date shown. Securities not classified by MSCI reflect country designations as of the date the report was generated. Sector exposure percentages reflect sector designations as currently classified by GICS.

Our capital allocation process is designed to build position size according to our conviction. Portfolio holdings develop through three stages: GardenSM, CropSM and HarvestSM. GardenSM investments are situations where we believe we are right, but there is not clear evidence that the profit cycle has taken hold, so positions are small. CropSM investments are holdings where we have gained conviction in the company's profit cycle, so positions are larger. HarvestSM investments are holdings that have exceeded our estimate of intrinsic value or holdings where there is a deceleration in the company's profit cycle. HarvestSM investments are generally being reduced or sold from the portfolios.

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned broker/dealer subsidiary of Artisan Partners Holdings LP. Artisan Partners Limited Partnership, an investment advisory firm and adviser to Artisan Partners Funds, is wholly owned by Artisan Partners Holdings LP.

© 2017 Artisan Partners. All rights reserved.

2/3/2017 A17515L_vR